Product nameUC2288, p21 inhibitor
DescriptionNovel, selective, cell permeable p21 inhibitor
- p21/Cip1/CKI/Waf1 Inhibitor
Cell-permeable, phenylcyclohexyl-urea based compound that selectively downregulates the expression of p21, independent of p53 expression, at either transcription or post-transcriptional level. Attenuates p21 protein levels with minimal effect on p21 protein stability. Has no significant effect on the activities of Raf kinases, VEGFR2 kinase, or the phosphorylation state of ERK. Effectively inhibits the growth of multiple cancer cell lines (GI50 = ~ 10 µM against NCI60 cell lines).
Storage instructionsShipped at Room Temperature. Store at +4°C. Store In the Dark.
Solubility overviewSoluble in ethanol to 100 mM and in DMSO to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
This product has been referenced in:
- Gupta R et al. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A 111:E3062-71 (2014). Read more (PubMed: 25024194) »
- Liu R et al. Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer. Future Med Chem 5:991-4 (2013). Read more (PubMed: 23734682) »
- Wettersten HI et al. A novel p21 attenuator which is structurally related to sorafenib. Cancer Biol Ther 14:278-85 (2013). Read more (PubMed: 23298903) »